vs
Ecovyst Inc.（ECVT）とPHIBRO ANIMAL HEALTH CORP（PAHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
PHIBRO ANIMAL HEALTH CORPの直近四半期売上が大きい（$373.9M vs $199.4M、Ecovyst Inc.の約1.9倍）。Ecovyst Inc.の前年同期比売上増加率が高い（34.0% vs 20.9%）。Ecovyst Inc.の直近四半期フリーキャッシュフローが多い（$22.9M vs $8.3M）。過去8四半期でPHIBRO ANIMAL HEALTH CORPの売上複合成長率が高い（19.2% vs 18.7%）
Ecovyst Inc.は持続可能な特殊材料をグローバルに提供する企業で、高性能触媒と機能性添加剤の開発・製造を行っています。産業製造、消費財、環境保護などの分野の顧客に対し、業務効率化と炭素排出削減を支援するソリューションを提供しています。
ファイブローアニマルヘルスコーポレーションは米国の動物健康・ミネラル栄養企業で、抗菌剤、抗コクシジウム剤、駆虫薬のほか、家畜用栄養補給剤、ワクチンなどを製品ラインナップに持っています。ミネラル栄養、機能材料、動物健康の3事業セグメントを中心に収益を上げ、米国、中南米、カナダ、欧州、中東、アフリカ、アジア太平洋地域で事業を展開しています。
ECVT vs PAHC — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $199.4M | $373.9M |
| 純利益 | — | $27.5M |
| 粗利率 | 23.4% | 35.5% |
| 営業利益率 | 10.9% | 13.5% |
| 純利益率 | — | 7.3% |
| 売上前年比 | 34.0% | 20.9% |
| 純利益前年比 | — | 762.1% |
| EPS（希薄化後） | $0.06 | $0.67 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $199.4M | $373.9M | ||
| Q3 25 | $204.9M | $363.9M | ||
| Q2 25 | $176.1M | $378.7M | ||
| Q1 25 | $143.1M | $347.8M | ||
| Q4 24 | $148.9M | $309.3M | ||
| Q3 24 | $153.9M | $260.4M | ||
| Q2 24 | $154.0M | $273.2M | ||
| Q1 24 | $141.6M | $263.2M |
| Q4 25 | — | $27.5M | ||
| Q3 25 | $-79.3M | $26.5M | ||
| Q2 25 | $6.0M | $17.2M | ||
| Q1 25 | $-3.6M | $20.9M | ||
| Q4 24 | — | $3.2M | ||
| Q3 24 | $14.3M | $7.0M | ||
| Q2 24 | $8.3M | $752.0K | ||
| Q1 24 | $1.2M | $8.4M |
| Q4 25 | 23.4% | 35.5% | ||
| Q3 25 | 25.4% | 32.9% | ||
| Q2 25 | 22.8% | 29.0% | ||
| Q1 25 | 13.3% | 30.1% | ||
| Q4 24 | 28.9% | 32.9% | ||
| Q3 24 | 29.3% | 32.1% | ||
| Q2 24 | 27.3% | 31.9% | ||
| Q1 24 | 23.5% | 30.2% |
| Q4 25 | 10.9% | 13.5% | ||
| Q3 25 | 13.8% | 14.1% | ||
| Q2 25 | 9.0% | 8.9% | ||
| Q1 25 | -0.7% | 9.6% | ||
| Q4 24 | 15.1% | 8.3% | ||
| Q3 24 | 17.9% | 6.8% | ||
| Q2 24 | 14.1% | 6.7% | ||
| Q1 24 | 9.5% | 7.6% |
| Q4 25 | — | 7.3% | ||
| Q3 25 | -38.7% | 7.3% | ||
| Q2 25 | 3.4% | 4.5% | ||
| Q1 25 | -2.5% | 6.0% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | 9.3% | 2.7% | ||
| Q2 24 | 5.4% | 0.3% | ||
| Q1 24 | 0.9% | 3.2% |
| Q4 25 | $0.06 | $0.67 | ||
| Q3 25 | $-0.69 | $0.65 | ||
| Q2 25 | $0.05 | $0.43 | ||
| Q1 25 | $-0.03 | $0.51 | ||
| Q4 24 | $-0.26 | $0.08 | ||
| Q3 24 | $0.12 | $0.17 | ||
| Q2 24 | $0.07 | $0.02 | ||
| Q1 24 | $0.01 | $0.21 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $197.2M | $74.5M |
| 総負債低いほど良い | $392.6M | $624.2M |
| 株主資本純資産 | $603.4M | $332.4M |
| 総資産 | $1.3B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | 0.65× | 1.88× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $197.2M | $74.5M | ||
| Q3 25 | $82.0M | $85.3M | ||
| Q2 25 | $69.6M | $77.0M | ||
| Q1 25 | $127.5M | $70.4M | ||
| Q4 24 | $131.4M | $67.1M | ||
| Q3 24 | $123.5M | $89.8M | ||
| Q2 24 | $83.3M | $114.6M | ||
| Q1 24 | $103.1M | $98.7M |
| Q4 25 | $392.6M | $624.2M | ||
| Q3 25 | $854.8M | $628.0M | ||
| Q2 25 | $856.6M | $631.7M | ||
| Q1 25 | $859.0M | $635.4M | ||
| Q4 24 | $860.8M | $639.1M | ||
| Q3 24 | $862.7M | $295.2M | ||
| Q2 24 | $862.4M | $312.1M | ||
| Q1 24 | $866.2M | — |
| Q4 25 | $603.4M | $332.4M | ||
| Q3 25 | $607.9M | $311.7M | ||
| Q2 25 | $692.4M | $285.7M | ||
| Q1 25 | $698.7M | $266.0M | ||
| Q4 24 | $700.5M | $246.8M | ||
| Q3 24 | $729.4M | $258.5M | ||
| Q2 24 | $717.3M | $256.6M | ||
| Q1 24 | $711.4M | $270.1M |
| Q4 25 | $1.3B | $1.4B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.8B | $1.4B | ||
| Q1 25 | $1.8B | $1.3B | ||
| Q4 24 | $1.8B | $1.3B | ||
| Q3 24 | $1.8B | $966.3M | ||
| Q2 24 | $1.8B | $982.2M | ||
| Q1 24 | $1.8B | $979.0M |
| Q4 25 | 0.65× | 1.88× | ||
| Q3 25 | 1.41× | 2.01× | ||
| Q2 25 | 1.24× | 2.21× | ||
| Q1 25 | 1.23× | 2.39× | ||
| Q4 24 | 1.23× | 2.59× | ||
| Q3 24 | 1.18× | 1.14× | ||
| Q2 24 | 1.20× | 1.22× | ||
| Q1 24 | 1.22× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $41.8M | $19.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $22.9M | $8.3M |
| FCFマージンFCF / 売上 | 11.5% | 2.2% |
| 設備投資強度設備投資 / 売上 | 9.4% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | — | 0.70× |
| 直近12ヶ月FCF直近4四半期 | $69.9M | $47.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $41.8M | $19.4M | ||
| Q3 25 | $55.3M | $9.3M | ||
| Q2 25 | $33.0M | $21.3M | ||
| Q1 25 | $10.3M | $43.2M | ||
| Q4 24 | $43.5M | $3.1M | ||
| Q3 24 | $59.9M | $12.6M | ||
| Q2 24 | $10.0M | $28.4M | ||
| Q1 24 | $36.5M | $11.4M |
| Q4 25 | $22.9M | $8.3M | ||
| Q3 25 | $53.2M | $-4.5M | ||
| Q2 25 | $7.8M | $8.1M | ||
| Q1 25 | $-14.0M | $35.4M | ||
| Q4 24 | $30.9M | $-4.7M | ||
| Q3 24 | $53.6M | $3.0M | ||
| Q2 24 | $-9.3M | $15.4M | ||
| Q1 24 | $19.1M | $1.7M |
| Q4 25 | 11.5% | 2.2% | ||
| Q3 25 | 26.0% | -1.2% | ||
| Q2 25 | 4.4% | 2.1% | ||
| Q1 25 | -9.8% | 10.2% | ||
| Q4 24 | 20.7% | -1.5% | ||
| Q3 24 | 34.9% | 1.2% | ||
| Q2 24 | -6.1% | 5.6% | ||
| Q1 24 | 13.5% | 0.6% |
| Q4 25 | 9.4% | 3.0% | ||
| Q3 25 | 1.0% | 3.8% | ||
| Q2 25 | 14.4% | 3.5% | ||
| Q1 25 | 16.9% | 2.2% | ||
| Q4 24 | 8.5% | 2.5% | ||
| Q3 24 | 4.1% | 3.7% | ||
| Q2 24 | 12.5% | 4.8% | ||
| Q1 24 | 12.3% | 3.7% |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | 5.52× | 1.24× | ||
| Q1 25 | — | 2.07× | ||
| Q4 24 | — | 0.97× | ||
| Q3 24 | 4.21× | 1.81× | ||
| Q2 24 | 1.20× | 37.80× | ||
| Q1 24 | 29.90× | 1.36× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
